Use of antiviral agents and other measures in an influenza pandemic.
Identifieur interne : 000349 ( Main/Curation ); précédent : 000348; suivant : 000350Use of antiviral agents and other measures in an influenza pandemic.
Auteurs : K. Groeneveld [Pays-Bas] ; J. Van Der NoordaaSource :
- The Netherlands journal of medicine [ 0300-2977 ] ; 2005.
Descripteurs français
- KwdFr :
- Acides sialiques (usage thérapeutique), Acétamides (usage thérapeutique), Antiviraux (usage thérapeutique), Grippe humaine (prévention et contrôle), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Guanidines (usage thérapeutique), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Oséltamivir (MeSH), Pays-Bas (MeSH), Pyrannes (usage thérapeutique), Risque (MeSH), Sialidase (antagonistes et inhibiteurs), Virus de la grippe A (MeSH), Zanamivir (MeSH), Épidémies de maladies (prévention et contrôle).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- prévention et contrôle : Grippe humaine, Épidémies de maladies.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acides sialiques, Acétamides, Antiviraux, Guanidines, Pyrannes.
- épidémiologie : Grippe humaine.
- Guides de bonnes pratiques cliniques comme sujet, Humains, Oséltamivir, Pays-Bas, Risque, Virus de la grippe A, Zanamivir.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Acetamides (therapeutic use), Antiviral Agents (therapeutic use), Disease Outbreaks (prevention & control), Guanidines (therapeutic use), Humans (MeSH), Influenza A virus (MeSH), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Netherlands (MeSH), Neuraminidase (antagonists & inhibitors), Oseltamivir (MeSH), Practice Guidelines as Topic (MeSH), Pyrans (therapeutic use), Risk (MeSH), Sialic Acids (therapeutic use), Zanamivir (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Acetamides, Antiviral Agents, Guanidines, Pyrans, Sialic Acids.
- geographic : Netherlands, Oseltamivir, Zanamivir.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza, Human.
- Humans, Influenza A virus, Practice Guidelines as Topic, Risk.
Abstract
The Dutch Ministry of Health asked the Health Council for advice on how to prepare for a possible influenza pandemic. In two advisory reports the Committee responsible indicated the measures that it believes would need to be taken if such a pandemic were to reach the Netherlands. During a pandemic, the Committee recommends that every resident of the Netherlands with influenza-like illness should be treated with neuraminidase inhibitors such as antiviral agents. This approach serves to mitigate the course of the disease, to reduce infectivity and to allow patients to build up immunity to the virus. Since up to 30% of the population could become ill, the Committee anticipates that a stock of five million courses of the neuraminidase inhibitor oseltamivir is sufficient. If a pandemic were to occur at a time that the stock does not exceed the present 225,000 courses, the committee advises restricting treatment to three specified groups of patients. If the first few patients are traced shortly after they fall ill, the Committee recommends treatment of the patient and postexposure prophylaxis for his/her close contacts. The Committee does not advocate prophylaxis in general, but it can envisage prophylaxis for particular groups of patients or under particular circumstances. The Committee believes that in order to reduce rapid spread of the virus, schools should be closed and events where large numbers of people gather in a confined space should be cancelled. Because this recommendation would have major social and economic consequences, the Committee understands that its implication will depend on the anticipated severity and extent of the pandemic. The Committee regards vaccination against influenza as the best means of protecting the population. The development of a vaccine should be the absolute priority.
PubMed: 16244380
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000349
Links to Exploration step
pubmed:16244380Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of antiviral agents and other measures in an influenza pandemic.</title><author><name sortKey="Groeneveld, K" sort="Groeneveld, K" uniqKey="Groeneveld K" first="K" last="Groeneveld">K. Groeneveld</name><affiliation wicri:level="1"><nlm:affiliation>Health Council of the Netherlands, PO Box 16052, 2500 BB The Hague, the Netherlands. k.groeneveld@gr.nl</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Health Council of the Netherlands, PO Box 16052, 2500 BB The Hague</wicri:regionArea></affiliation></author><author><name sortKey="Van Der Noordaa, J" sort="Van Der Noordaa, J" uniqKey="Van Der Noordaa J" first="J" last="Van Der Noordaa">J. Van Der Noordaa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16244380</idno><idno type="pmid">16244380</idno><idno type="wicri:Area/Main/Corpus">000349</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000349</idno><idno type="wicri:Area/Main/Curation">000349</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000349</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of antiviral agents and other measures in an influenza pandemic.</title><author><name sortKey="Groeneveld, K" sort="Groeneveld, K" uniqKey="Groeneveld K" first="K" last="Groeneveld">K. Groeneveld</name><affiliation wicri:level="1"><nlm:affiliation>Health Council of the Netherlands, PO Box 16052, 2500 BB The Hague, the Netherlands. k.groeneveld@gr.nl</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Health Council of the Netherlands, PO Box 16052, 2500 BB The Hague</wicri:regionArea></affiliation></author><author><name sortKey="Van Der Noordaa, J" sort="Van Der Noordaa, J" uniqKey="Van Der Noordaa J" first="J" last="Van Der Noordaa">J. Van Der Noordaa</name></author></analytic><series><title level="j">The Netherlands journal of medicine</title><idno type="ISSN">0300-2977</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Disease Outbreaks (prevention & control)</term><term>Guanidines (therapeutic use)</term><term>Humans (MeSH)</term><term>Influenza A virus (MeSH)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Netherlands (MeSH)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (MeSH)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Pyrans (therapeutic use)</term><term>Risk (MeSH)</term><term>Sialic Acids (therapeutic use)</term><term>Zanamivir (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides sialiques (usage thérapeutique)</term><term>Acétamides (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Guanidines (usage thérapeutique)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Oséltamivir (MeSH)</term><term>Pays-Bas (MeSH)</term><term>Pyrannes (usage thérapeutique)</term><term>Risque (MeSH)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Virus de la grippe A (MeSH)</term><term>Zanamivir (MeSH)</term><term>Épidémies de maladies (prévention et contrôle)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Antiviral Agents</term><term>Guanidines</term><term>Pyrans</term><term>Sialic Acids</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Netherlands</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acides sialiques</term><term>Acétamides</term><term>Antiviraux</term><term>Guanidines</term><term>Pyrannes</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Influenza A virus</term><term>Practice Guidelines as Topic</term><term>Risk</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Oséltamivir</term><term>Pays-Bas</term><term>Risque</term><term>Virus de la grippe A</term><term>Zanamivir</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Dutch Ministry of Health asked the Health Council for advice on how to prepare for a possible influenza pandemic. In two advisory reports the Committee responsible indicated the measures that it believes would need to be taken if such a pandemic were to reach the Netherlands. During a pandemic, the Committee recommends that every resident of the Netherlands with influenza-like illness should be treated with neuraminidase inhibitors such as antiviral agents. This approach serves to mitigate the course of the disease, to reduce infectivity and to allow patients to build up immunity to the virus. Since up to 30% of the population could become ill, the Committee anticipates that a stock of five million courses of the neuraminidase inhibitor oseltamivir is sufficient. If a pandemic were to occur at a time that the stock does not exceed the present 225,000 courses, the committee advises restricting treatment to three specified groups of patients. If the first few patients are traced shortly after they fall ill, the Committee recommends treatment of the patient and postexposure prophylaxis for his/her close contacts. The Committee does not advocate prophylaxis in general, but it can envisage prophylaxis for particular groups of patients or under particular circumstances. The Committee believes that in order to reduce rapid spread of the virus, schools should be closed and events where large numbers of people gather in a confined space should be cancelled. Because this recommendation would have major social and economic consequences, the Committee understands that its implication will depend on the anticipated severity and extent of the pandemic. The Committee regards vaccination against influenza as the best means of protecting the population. The development of a vaccine should be the absolute priority.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16244380</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-2977</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>9</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Netherlands journal of medicine</Title><ISOAbbreviation>Neth J Med</ISOAbbreviation></Journal><ArticleTitle>Use of antiviral agents and other measures in an influenza pandemic.</ArticleTitle><Pagination><MedlinePgn>339-43</MedlinePgn></Pagination><Abstract><AbstractText>The Dutch Ministry of Health asked the Health Council for advice on how to prepare for a possible influenza pandemic. In two advisory reports the Committee responsible indicated the measures that it believes would need to be taken if such a pandemic were to reach the Netherlands. During a pandemic, the Committee recommends that every resident of the Netherlands with influenza-like illness should be treated with neuraminidase inhibitors such as antiviral agents. This approach serves to mitigate the course of the disease, to reduce infectivity and to allow patients to build up immunity to the virus. Since up to 30% of the population could become ill, the Committee anticipates that a stock of five million courses of the neuraminidase inhibitor oseltamivir is sufficient. If a pandemic were to occur at a time that the stock does not exceed the present 225,000 courses, the committee advises restricting treatment to three specified groups of patients. If the first few patients are traced shortly after they fall ill, the Committee recommends treatment of the patient and postexposure prophylaxis for his/her close contacts. The Committee does not advocate prophylaxis in general, but it can envisage prophylaxis for particular groups of patients or under particular circumstances. The Committee believes that in order to reduce rapid spread of the virus, schools should be closed and events where large numbers of people gather in a confined space should be cancelled. Because this recommendation would have major social and economic consequences, the Committee understands that its implication will depend on the anticipated severity and extent of the pandemic. The Committee regards vaccination against influenza as the best means of protecting the population. The development of a vaccine should be the absolute priority.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Groeneveld</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Council of the Netherlands, PO Box 16052, 2500 BB The Hague, the Netherlands. k.groeneveld@gr.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Noordaa</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Neth J Med</MedlineTA><NlmUniqueID>0356133</NlmUniqueID><ISSNLinking>0300-2977</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011714">Pyrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16244380</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000349 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000349 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:16244380
|texte= Use of antiviral agents and other measures in an influenza pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:16244380" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |